Supplementary Table 1, Figures 1-5 from Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy

Autor: Shu-Hsia Chen, Eric C. Ko, Ping-Ying Pan, Lu-Hai Wang, Johnny Kao, Robert Ferris, Max Sung, Myron Schwartz, Celia Divino, John Mandeli, Junko Ozao, Brian A. Coakley, Samuel Eisenstein, Neil Gildener-Leapman, Ge Ma, Hui-Ming Chen
Rok vydání: 2023
DOI: 10.1158/1078-0432.22457793
Popis: Supplementary Table 1. Characteristics of the enrolled patients. Supplementary Figure 1. PBMCs were obtained from patients enrolled in the clinical trials at time points A (pre-sunitinib treatment), B (7 days post-sunitinib treatment), and C (6-30 days post-SBRT). Supplementary Figure 2. The number of pSTAT1+ in CD33+CD14+CD16+ (upper panels) and CD33+CD14+CD16- (lower panels) cells in PBMC from all patients and sunitinib-responders and non-responders based on Tbet+ CD4 T cell-criteria, was determined at the indicated time points. (*p < 0.05; ***p < 0.001) Supplementary Figure 3. The percentage and cell numbers of CD33+CD11b+ Supplementary Figure 4. The percentage of Tbet-expressing CD4 and CD8 T cells in PBMC from all patients, and patients who were separated into sunitinib-responders and non-responders was determined at the indicated time points based on the myeloid cell-based classification Supplementary Figure 5.(A) Mouse monocytic MDSC were left untreated (red) or treated with sunitinib (250 nM, blue) for 48 hrs. The apoptotic cells (Annexin V+) and phosphorylated STAT3 were assessed by flow cytometry. (B) Flow cytometric histogram of CD206+ in CD33+CD14+CD16- (blue) and CD33+CD14+CD16+ (red) populations (left panel). Mean fluorescent intensity of CD206+ was shown on the right panel. (C) Human CD33+CD14+CD16- and CD33+CD14+CD16+ populations were sorted from total PBMC. The mRNA expression of iNOS, MRC1, ARG1 and ARG2 were standardized as the fold changes using CD33+CD14+CD16- population as the base line. (C) The suppressive activity of sorted human CD33+CD14+CD16+ cells against the proliferation of autologous CD4+ T cells in the presence or absence of arginase inhibitor (Nor-NOHA, 100microM) was presented. (*p < 0.05; ***p < 0.001)
Databáze: OpenAIRE